Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Elicio Therapeutics Inc.(ELTX)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ELTX
10/02/2026: ELTX (1-star) is currently NOT-A-BUY. Pass it for now.
Elicio Therapeutics is a clinical-stage biotechnology company focused on developing cancer vaccines through its proprietary Amphiphile (AMP) platform. Its core investment story centers on the potential of this technology to improve immunotherapy effectiveness by targeting lymph nodes, specifically for hard-to-treat KRAS-mutated tumors. While the company has a unique clinical approach, it faces high execution risks, lacks recurring revenue, and is currently dependent on outside financing to fund its operations. Investors should closely monitor clinical trial outcomes for the ELI-002 vaccine and any potential pharmaceutical partnerships. This stock is best suited for high-risk growth investors comfortable with the significant volatility common in early-stage biotech investments.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high-growth potential via its platform but lacks the revenue base typically sought by growth investors. |
| Momentum investor | Mixed fit | Momentum fit is conditional on positive clinical data readouts driving stock price volatility. |
| Value investor | Weak fit | The company lacks current earnings or tangible assets, making traditional value metrics inapplicable. |
| Dividend investor | Weak fit | The company is a cash-burning biotech that does not pay dividends. |
| Low-risk investor | Weak fit | The company involves extreme risks associated with early-stage clinical development and potential total loss of capital. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage stocks are prone to extreme price swings based on trial results and regulatory updates. |
| Valuation risk | Medium / high | Valuation is speculative and heavily dependent on long-term clinical success. |
| Competition risk (Immunotherapy) | High | Well-funded competitors are also working on cancer vaccines, creating significant competitive pressure. |
| Business quality | Medium | The business is dependent on a specific, unproven technology platform. |
| Dividend income | Low / none | The company does not generate the cash flow necessary to support dividend payments. |
| Execution risk | High | Success requires perfect execution of complex, expensive, and unpredictable clinical trials. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -34.82% | Avg. Invested days 39 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  4.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/02/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 50.46M USD | Price to earnings Ratio - | 1Y Target Price 13.67 |
Price to earnings Ratio - | 1Y Target Price 13.67 | ||
Volume (30-day avg) 347.1K shares | Beta 1.86 | 52 Weeks Range 1.71 - 16.00 | Updated Date 10/02/2026 |
52 Weeks Range 1.71 - 16.00 | Updated Date 10/02/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.11 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Clinical Research and Development | Researching and developing the AMP platform and vaccine candidates. | The company currently makes no money and loses cash while testing its medicines in clinical trials. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 39.68M | Price to Sales(TTM) - |
Enterprise Value 39.68M | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.61 | Shares Outstanding 26.28M | Shares Floating 19.20M |
Shares Outstanding 26.28M | Shares Floating 19.20M | ||
Percent Insiders 26.97 | Percent Institutions 16.25 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Elicio Therapeutics Inc.
Exchange NASDAQ | Headquarters Boston, MA, United States | ||
IPO Launch date 2021-02-05 | CEO, President & Director Mr. Robert T. Connelly | ||
Sector Healthcare | Industry Biotechnology | Full time employees 33 | Website https://elicio.com |
Full time employees 33 | Website https://elicio.com | ||
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.